skip to main content
Idioma:

Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome

Patti, Giuseppe ; Fattirolli, Francesco ; De Luca, Leonardo ; Renda, Giulia ; Marcucci, Rossella ; Parodi, Guido ; Perna, Gian Piero ; Andreotti, Felicita ; Ghiglieno, Chiara ; Fedele, Francesco ; Marchionni, Niccolò

Biomedicine & pharmacotherapy, 2021-08, Vol.140, p.111783-111783, Article 111783 [Periódico revisado por pares]

Elsevier Masson SAS

Texto completo disponível

Citações Citado por
  • Título:
    Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome
  • Autor: Patti, Giuseppe ; Fattirolli, Francesco ; De Luca, Leonardo ; Renda, Giulia ; Marcucci, Rossella ; Parodi, Guido ; Perna, Gian Piero ; Andreotti, Felicita ; Ghiglieno, Chiara ; Fedele, Francesco ; Marchionni, Niccolò
  • Assuntos: Antithrombotic therapy ; Bleeding ; Chronic coronary syndrome ; Myocardial infarction
  • É parte de: Biomedicine & pharmacotherapy, 2021-08, Vol.140, p.111783-111783, Article 111783
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: Despite recent achievements in secondary cardiovascular prevention, the risk of further events in patients with chronic coronary syndromes (CCS) remains elevated. Highest risk is seen in patients with recurrent events, comorbidities or multisite atherosclerosis. Optimising antithrombotic strategies in this setting may significantly improve outcomes. The higher the baseline risk, the higher the absolute event reduction with approaches using combined antithrombotic treatments. Tailoring such strategies to the individual patient risk appears crucial to achieve net benefit (i.e., substantial ischaemic event prevention at a limited cost in terms of bleeding). This paper focuses on antithrombotic and non-pharmacological approaches to secondary cardiovascular disease prevention in CCS. In particular, we critically review current evidence on the use of dual antithrombotic therapy, including the newest approach of aspirin plus low-dose anticoagulation and its net clinical outcome according to baseline risk. •The risk of recurrent events remains high in patients with CCS.•Antithrombotic approaches are SAPT or DAPT or low-dose rivaroxaban plus aspirin.•An antithrombotic approach tailored to both ischaemic and bleeding risk is crucial.•Healthy lifestyle and risk factor control further decrease recurrent events.
  • Editor: Elsevier Masson SAS
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.